LMO2 and T-cell acute lymphoblastic leukemia: Therefore, in the future, our aim is to extend these compounds to potentially achieve binding geography like that seen for the anti–LMO2 iDAb and that could achieve the same LMO2 stable conformation change that the iDAb causes, with the similar effects on the LMO2 protein complex function in T cell acute leukemia.